220506-49-0

Upstream product

• 847026-36-2 N-[2-(4-benzylpiperazin-1-yl)ethyl]-pyridin-2-ylamine 
• 2719-27-9 cyclohexanylcarbonyl chloride 
• 5221-37-4 2-chloro-N-pyridin-2-ylacetamide 
• 196308-76-6 N-formylmethyl-N-(pyridin-2-yl)-cyclohexanecarboxamide 
• 2759-28-6 1-phenylmethylpiperazine 
• 196308-75-5 N-(2,2-Dimethoxyethyl)-N-(pyridin-2-yl)-cyclohexanecarboxamide 
• 847026-35-1 2-(4-benzylpiperazin-1-yl)-N-pyridin-2-ylacetamide 

Downstream Products

• 847026-37-3 N-(2-(1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide 

Relevant academic research and scientific papers

N-Oxide analogs of WAY-100635: New high affinity 5-HT1A receptor antagonists

WAY-100635 [N-(2-(1-(4-(2-methoxyphenyl)piperazinyl)ethyl))-N-(2-pyridinyl) cyclohexanecarboxamide] 1 and its O-desmethyl derivative DWAY 2 are well-known high affinity 5-HT1A receptor antagonists, which when labeled with carbon-11 (β+/su

1,4-disubstituted piperazines

Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are 1,4-disubstituted piperazine derivatives. The methods comprise the administration of the novel compounds of the invention,